Immunoblotting: 1 - 5 μg/mL. Immunoprecipitation: 10 - 20 μg/mL. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1 mg/mL
Buffer
PBS, 0.08 % Sodium Azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
-20 °C
Informationen zur Lagerung
Store the antibody (in aliquots) at -20 °C.
Anderton, Yee, Smith, Crook, White, Allday: "Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma." in: Oncogene, Vol. 27, Issue 4, pp. 421-33, (2008) (PubMed).
Sugaya, Watanabe, Yang, Starost, Kobayashi, Atkins, Borris, Hanan, Schimel, Bryant, Roberts, Skobe, Staskus, Kaldis, Blauvelt: "Lymphatic dysfunction in transgenic mice expressing KSHV k-cyclin under the control of the VEGFR-3 promoter." in: Blood, Vol. 105, Issue 6, pp. 2356-63, (2005) (PubMed).
Järviluoma, Koopal, Räsänen, Mäkelä, Ojala: "KSHV viral cyclin binds to p27KIP1 in primary effusion lymphomas." in: Blood, Vol. 104, Issue 10, pp. 3349-54, (2004) (PubMed).
Human herpervirus-8 (HHV-8) cyclin is a component of the HHV-8 virus particle. HHV8 has been found to be associated with three different diseases observed in AIDS patients, kaposi's sarcoma, primary effusion lymphoma (which is a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman's disease. To date there is much evidence to support a direct role for HHV8 in kaposi's sarcoma.Synonyms: HHV-8, KHSV